JP2024528569A - プラダー・ウィリー症候群を治療するためのカンナビジオール酸エステル - Google Patents

プラダー・ウィリー症候群を治療するためのカンナビジオール酸エステル Download PDF

Info

Publication number
JP2024528569A
JP2024528569A JP2024500204A JP2024500204A JP2024528569A JP 2024528569 A JP2024528569 A JP 2024528569A JP 2024500204 A JP2024500204 A JP 2024500204A JP 2024500204 A JP2024500204 A JP 2024500204A JP 2024528569 A JP2024528569 A JP 2024528569A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
use according
cbda
cannabinoid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528569A5 (https=
Inventor
スウィサ，レシェフ
シャー，ロテム
シャラバーニ，ロン
タム，ヨセフ
Original Assignee
イーピーエム（アイピー）， インコーポレイテッド
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーピーエム（アイピー）， インコーポレイテッド, イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． filed Critical イーピーエム（アイピー）， インコーポレイテッド
Publication of JP2024528569A publication Critical patent/JP2024528569A/ja
Publication of JP2024528569A5 publication Critical patent/JP2024528569A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2024500204A 2021-07-13 2022-07-07 プラダー・ウィリー症候群を治療するためのカンナビジオール酸エステル Pending JP2024528569A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163221006P 2021-07-13 2021-07-13
US63/221,006 2021-07-13
US202163276668P 2021-11-08 2021-11-08
US63/276,668 2021-11-08
PCT/IL2022/050734 WO2023286047A1 (en) 2021-07-13 2022-07-07 Cannabidiolic acid esters for treating prader-willi syndrome

Publications (2)

Publication Number Publication Date
JP2024528569A true JP2024528569A (ja) 2024-07-30
JP2024528569A5 JP2024528569A5 (https=) 2025-07-08

Family

ID=84919088

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500204A Pending JP2024528569A (ja) 2021-07-13 2022-07-07 プラダー・ウィリー症候群を治療するためのカンナビジオール酸エステル

Country Status (7)

Country Link
US (1) US20240316073A1 (https=)
EP (1) EP4370106A4 (https=)
JP (1) JP2024528569A (https=)
AU (1) AU2022312764A1 (https=)
CA (1) CA3224271A1 (https=)
IL (1) IL310009A (https=)
WO (1) WO2023286047A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3062814C (en) * 2017-04-27 2023-11-14 Insys Development Company, Inc. Stable cannabinoid formulations
US12403114B2 (en) * 2019-03-12 2025-09-02 Epm (Ip), Inc. Cannabinoid acid ester compositions and uses thereof
WO2021137224A1 (en) * 2020-01-01 2021-07-08 Epm Group, Inc. Cannabidiolic acid esters for treating muscular dystrophy
CN113087599A (zh) * 2020-01-08 2021-07-09 成都百裕制药股份有限公司 大麻二酚衍生物及其制备方法和在医药上的应用

Also Published As

Publication number Publication date
IL310009A (en) 2024-03-01
AU2022312764A1 (en) 2024-01-18
US20240316073A1 (en) 2024-09-26
WO2023286047A1 (en) 2023-01-19
EP4370106A1 (en) 2024-05-22
EP4370106A4 (en) 2025-05-21
CA3224271A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
JP6941224B2 (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
RU2468797C2 (ru) Способ и композиция для лечения воспалительных нарушений
US9770430B2 (en) Desferrioxamine-metal complexes for the treatment of immune-related disorders
JP3114895B2 (ja) 炎症性疾患の処置のための薬剤調製物
JP6462045B2 (ja) スルフォラファンの単離及び精製
JP2002511482A (ja) 胆汁酸および胆汁酸誘導体の脂肪酸誘導体
CA3132637A1 (en) Cannabinoid acid ester compositions and uses thereof
KR101005819B1 (ko) 데히드로에피안드로스테론의 네뷸라이저 제제 및 이의조성물을 사용한 천식 또는 만성 폐색성 폐 질환의 치료방법
EP3563873A1 (en) Application of combination of polyethylene glycol and local anesthetic in non-narcotic analgesia
KR20220035512A (ko) 비강내 에피네프린 제제 및 질환의 치료 방법
JP2023089077A (ja) Ｎ－アセチル又はｎ－アシルアミノ酸を含むアトピー又は痒み症治療用組成物
WO2021224924A1 (en) Cannabidiolic acid esters for treating respiratory distress including acute respiratory distress syndrome and coronavirus
JP2024528569A (ja) プラダー・ウィリー症候群を治療するためのカンナビジオール酸エステル
HK40107023A (zh) 用於治疗普拉德-威利综合征的大麻二醇酸酯
US20220105082A1 (en) New formulations containing leukotriene receptor antagonists
CN117813081A (zh) 用于治疗普拉德-威利综合征的大麻二醇酸酯
Mustafa et al. Venlafaxine loaded novasomes for intranasal delivery: Mucoadhesion, permeation and pharmacokinetics study
WO2021137224A1 (en) Cannabidiolic acid esters for treating muscular dystrophy
WO2018002888A1 (en) Methods of making low odor choline salts of an organic compound
US11858908B2 (en) Compositions and methods for inhibiting IDO1
JP2001506628A (ja) 抗酸化剤としてのエキレニンの使用
KR20240099975A (ko) 신규 화합물 및 이를 포함하는 간질환 치료용 약학적 조성물
CN118786134A (zh) Dhea衍生的类固醇

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250630